Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.78 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.57 |
| ▸ | IKZF2 | Q9UKS7 | 4/20 | 0.49 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | TNF | P01375 | 1/20 | 0.48 |
| ▸ | IL1B | P01584 | 1/20 | 0.48 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.48 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4307565 | 1.00 | CRBN (0.78) | CRBNDDB1IKZF2IKZF3BRD4 | |
| SCHEMBL4315200 | 1.00 | CRBN (0.78) | CRBNDDB1IKZF2IKZF3BRD4 | |
| SCHEMBL4307848 | 0.90 | CRBN (0.78) | CRBNDDB1IKZF3BRD4TNF | |
| SCHEMBL4307572 | 0.90 | CRBN (0.78) | CRBNDDB1IKZF3BRD4TNF | |
| SCHEMBL4307568 | 0.90 | CRBN (0.78) | CRBNDDB1IKZF3BRD4TNF | |
| SCHEMBL20234431 | 0.88 | CRBN (1.00) | CRBNDDB1IKZF2IKZF3BRD4 | |
| SCHEMBL29440001 | 0.88 | CRBN (1.00) | CRBNDDB1IKZF2IKZF3BRD4 | |
| SCHEMBL501751 | 0.88 | CRBN (1.00) | CRBNDDB1IKZF2IKZF3BRD4 | |
| SCHEMBL22564891 | 0.85 | CRBN (0.57) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL20128634 | 0.82 | CRBN (0.76) | CRBNDDB1IKZF3BRD4TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298882-A1 | THIOXOISOINDOLINE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2009-12-03 | — | — | US | claimed |
| WO-2009139880-A1 | THIOXOISOINDOLINE COMPOUNDS AND COMPOSITIONS AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2009-11-19 | — | — | WO | claimed |
| US-20090298882-A1 | THIOXOISOINDOLINE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2009-12-03 | — | — | US | disclosed |
| WO-2009139880-A1 | THIOXOISOINDOLINE COMPOUNDS AND COMPOSITIONS AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298882-A1 | THIOXOISOINDOLINE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | TPMT, CYP3A7, UGT2B7 | CRBN 4405/4885DDB1 1975/4885IKZF2 3330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.